Disentangling Schwann Cell and Neuronal TRPA1 Function in Mouse Models of Familial Episodic Pain Syndrome

preprint OA: gold
⚙ AI-generated summary by qwen3.7-flash, 2026-08-29 ⓘ

Mouse models reveal that neuronal TRPA1 mediates acute nociception while Schwann cell TRPA1 drives mechanical allodynia in Familial Episodic Pain Syndrome, linking these effects to oxidative stress.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by qwen3.7-flash, 2026-08-29 · read from full text ⓘ

This study investigates the distinct roles of mutant TRPA1 channels in Familial Episodic Pain Syndrome by creating mouse models where the gain-of-function mutation is selectively expressed in either sensory neurons or Schwann cells. Behavioral assays demonstrated that while neuronal TRPA1 mediates acute nociception, Schwann cell-specific expression drives mechanical allodynia triggered by cold, fasting, and stress, a process linked to increased reactive oxygen species in sciatic nerves. The researchers found that antioxidant treatment could reduce these pain responses, highlighting the specific contribution of non-neuronal TRPA1 activity to chronic pain mechanisms. The paper does not explicitly discuss endometriosis or adenomyosis; it was included in the corpus via a keyword match in the upstream search index.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Summary Familial Episodic Pain Syndrome (FEPS) is a rare inherited disorder characterized by episodes of severe upper-body pain triggered by different stimuli including cold, stress, or fasting. A gain-of-function point mutation (N855S) in the Transient Receptor Potential Ankyrin 1 (TRPA1) ion channel has been identified in affected individuals, altering its biophysical properties, and leading to sustained nociceptive signaling. While TRPA1 is predominantly studied in sensory neurons, recent findings highlight its key modulatory role for Schwann cells in chronic pain. Here, we investigated the cell-specific contributions of mutant TRPA1 (TRPA1*) in FEPS by developing mouse models with TRPA1* selectively expressed in either Schwann cells or sensory neurons, using CRISPR-based and Cre-loxP strategies. Patch-clamp analyses confirmed that TRPA1* exhibits enhanced current responses to agonists compared to wild-type. Through behavioral assays we revealed that TRPA1* expressed in sensory neurons mediates acute nociception, while TRPA1* in Schwann cells drives mechanical allodynia in response to subthreshold doses of TRPA1 agonists and to physiological pain triggers commonly observed in FEPS patients, including fasting, cold exposure, and restraint stress. Pain responses were associated with the increase in reactive oxygen species (ROS) and accumulation of 4-hydroxynonenal (4-HNE) in TRPA1* sciatic nerves and these effects were reduced by a treatment with an antioxidant. We reveal distinct roles of neuronal and non-neuronal TRPA1 in pain and provide novel in vivo models to investigate the mechanisms of chronic pain in FEPS and related channelopathies. Overall, this study offers new insights into the development of targeted therapies for Schwann cell-TRPA1 to relieve pain in affected individuals.
Full text 1,896 characters · extracted from oa-doi-fallback · click to expand
Summary Familial Episodic Pain Syndrome (FEPS) is a rare inherited disorder characterized by episodes of severe upper-body pain triggered by different stimuli including cold, stress, or fasting. A gain-of-function point mutation (N855S) in the Transient Receptor Potential Ankyrin 1 (TRPA1) ion channel has been identified in affected individuals, altering its biophysical properties, and leading to sustained nociceptive signaling. While TRPA1 is predominantly studied in sensory neurons, recent findings highlight its key modulatory role for Schwann cells in chronic pain. Here, we investigated the cell-specific contributions of mutant TRPA1 (TRPA1*) in FEPS by developing mouse models with TRPA1* selectively expressed in either Schwann cells or sensory neurons, using CRISPR-based and Cre-loxP strategies. Patch-clamp analyses confirmed that TRPA1* exhibits enhanced current responses to agonists compared to wild-type. Through behavioral assays we revealed that TRPA1* expressed in sensory neurons mediates acute nociception, while TRPA1* in Schwann cells drives mechanical allodynia in response to subthreshold doses of TRPA1 agonists and to physiological pain triggers commonly observed in FEPS patients, including fasting, cold exposure, and restraint stress. Pain responses were associated with the increase in reactive oxygen species (ROS) and accumulation of 4-hydroxynonenal (4-HNE) in TRPA1* sciatic nerves and these effects were reduced by a treatment with an antioxidant. We reveal distinct roles of neuronal and non-neuronal TRPA1 in pain and provide novel in vivo models to investigate the mechanisms of chronic pain in FEPS and related channelopathies. Overall, this study offers new insights into the development of targeted therapies for Schwann cell-TRPA1 to relieve pain in affected individuals. Competing Interest Statement The authors have declared no competing interest.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-10-05T06:31:09.473872+00:00